Regulatory Affairs 101: Introduction to Expedited Regulatory Pathways
Developing a novel drug, including discovery, nonclinical toxicology studies, initial clinical trials, and thorough pivotal studies, may take many years. Once an applicant has generated this comprehensive body of data, the final step prior to regulatory approval is Health Authority review of the mar...
Main Authors: | Erica M. Cox, Anita V. Edmund, Erica Kratz, Sarah H. Lockwood, Aishwarya Shankar |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2020-05-01
|
Series: | Clinical and Translational Science |
Online Access: | https://doi.org/10.1111/cts.12745 |
Similar Items
-
Regulatory Affairs 101: Introduction to Investigational New Drug Applications and Clinical Trial Applications
by: Davy Chiodin, et al.
Published: (2019-07-01) -
Medical Device Apps: An Introduction to Regulatory Affairs for Developers
by: Keutzer, Lina, et al.
Published: (2020-06-01) -
ASEAN Regulatory Affairs Study on Generic Drugs
by: Chun-Huei Chiu, et al.
Published: (2017) -
Transparency in Medicines Regulatory Affairs Reclaiming Missed Opportunities
by: Y A Vawda, et al.
Published: (2017-12-01) -
CD101 genetic variants modify regulatory and conventional T cell phenotypes and functions
by: Laura E. Richert-Spuhler, et al.
Published: (2021-06-01)